Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DEBIO 9902

Drug Profile

DEBIO 9902

Alternative Names: DEBIO 9902 SR; DEBIO-9902 SR implants; N-(5-chloro-2-hydroxy-3-methoxy-benzylidene)-huperzine A; Oral ZT 1; ZT 1 Long Acting; ZT 1 sustained-release SC implant; ZT-1; ZT-1 LA

Latest Information Update: 16 Aug 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chinese Academy of Sciences; Jiangsu Yangtze Pharma
  • Developer Debiopharm
  • Class Alkaloids; Antidementias; Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 23 Oct 2008 Debiopharm Group completes phase II (BRAINz) trial in Alzheimer's disease
  • 21 Oct 2008 Phase-I clinical trials in Alzheimer's disease of new tablet formulation in healthly elderly volunteers in USA (PO)
  • 06 Mar 2008 The phase II (BRAINz) trial is ongoing for Alzheimer's disease
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top